These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 22883769)

  • 1. Re: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
    Schaeffer EM
    J Urol; 2012 Sep; 188(3):835-6. PubMed ID: 22883769
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Liao et al.: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. (Urology 2011;78:1373-1379).
    Mandal S; Patil SB; Goel A
    Urology; 2012 May; 79(5):1192; author reply 1192-3. PubMed ID: 22546407
    [No Abstract]   [Full Text] [Related]  

  • 3. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.
    Wasson JH; Reda DJ; Bruskewitz RC; Elinson J; Keller AM; Henderson WG
    N Engl J Med; 1995 Jan; 332(2):75-9. PubMed ID: 7527493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of transurethral resection of the prostate and medical treatment for the patient with moderate symptoms of benign prostatic hyperplasia.
    Yamamoto M; Hibi H; Miyake K
    Nagoya J Med Sci; 1996 Mar; 59(1-2):11-6. PubMed ID: 8725483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
    Tsujimura A; Takao T; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Kiuchi H; Hirai T; Tsujimoto Y; Miura H; Kanno N; Higashino M; Nakamura Y; Nishimura K; Nonomura N
    Urology; 2011 Nov; 78(5):1058-62. PubMed ID: 21908025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
    Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
    J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
    Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
    J Med Assoc Thai; 2007 Sep; 90(9):1821-7. PubMed ID: 17957925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.
    Oelke M; Baard J; Wijkstra H; de la Rosette JJ; Jonas U; Höfner K
    Eur Urol; 2008 Aug; 54(2):419-26. PubMed ID: 18325657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
    Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
    J Med Assoc Thai; 2007 Nov; 90(11):2301-9. PubMed ID: 18181311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study.
    Parsons JK; Palazzi-Churas K; Bergstrom J; Barrett-Connor E
    J Urol; 2010 Sep; 184(3):1040-4. PubMed ID: 20643424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels].
    Yasukawa A; Nihira H; Matsuki S; Fujii M; Fujiwara H; Kitano T; Kodama M; Ukai R; Tado O; Sagami K
    Hinyokika Kiyo; 1984 Apr; 30(4):537-43. PubMed ID: 6207714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
    Parsons JK; Sarma AV; McVary K; Wei JT
    J Urol; 2009 Dec; 182(6 Suppl):S27-31. PubMed ID: 19846130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia.
    Parsons JK; Im R
    J Urol; 2009 Oct; 182(4):1463-8. PubMed ID: 19683313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III).
    Rohrmann S; De Marzo AM; Smit E; Giovannucci E; Platz EA
    Prostate; 2005 Jan; 62(1):27-33. PubMed ID: 15389816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.